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Little is known about practice patterns regarding the diagnosis and management of
idiopathic pulmonary fibrosis (IPF). This study attempts to define the practice patterns of
academic pulmonologists caring for patients with IPF. Academic pulmonologists in the
United States were surveyed electronically. Completed surveys were received from 272
respondents (representing approximately 10% of academic pulmonologists). The majority
agreed that high-resolution computed tomography can establish the diagnosis of IPF, and
that surgical lung biopsy is indicated when the diagnosis remains unclear. Bronchoscopy is
little utilized. Most respondents treat patients with medications, but there is no consensus
regarding treatment regimen. These results suggest there is general consensus regarding
the approach to diagnosis, but that there is no consensus about medical management in IPF.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common form
of idiopathic interstitial pneumonia, with an estimatedElsevier Ltd. All rights reserved.
plus cytotoxic therapy; P,
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206 4694;
ucsf.edu (H.R. Collard).prevalence of up to 42 per 100,000 people.1 There are no
proven therapies for IPF and median survival is around 3
years from the time of diagnosis.2–5 Because of its rarity,
severity and lack of response to therapy, IPF is confusing and
frustrating to practicing pulmonologists.
The American Thoracic Society (ATS), European Respira-
tory Society (ERS) and the American College of Chest
Physicians (ACCP) produced a joint statement in 2000
outlining the current definition of IPF and recommending
an approach to its diagnosis and management.2 This
statement defined IPF as a specific form of chronic fibrosing
interstitial pneumonia with the histologic appearance of
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or open) biopsy. In the absence of surgical lung biopsy,
criteria for a presumptive clinical diagnosis of IPF were
developed that centered around a typical appearance on
high-resolution computed tomography (HRCT) of the chest.2
These clinical criteria have since been validated, and
although they have poor sensitivity, they are highly
specific.6–8 While careful to state that no therapy has been
proven beneficial in the treatment of IPF, the ATS/ERS/ACCP
statement recommended considering combination therapy
with corticosteroid and cytotoxic (azathioprine or cyclopho-
sphamide) drugs.
Little is known about current practice patterns regarding
the diagnosis and management of IPF. In addition, it is
unknown whether these practice patterns are consistent
with the recent consensus recommendations. Academic
physicians are leaders in the continuing education of the
pulmonary community through publication of research
and review articles, presentations at conferences, and
day-to-day interaction with community providers and
physicians in training. Knowledge of academic physicians’
approach to caring for patients with IPF would, therefore,
directly inform the current standard of care for diagnosis
and management of this condition. This study was
designed to define the practice patterns of academic
pulmonologists caring for patients with IPF and assess the
degree to which these patterns are consistent with
consensus recommendations.Methods
Survey population
A search for Accreditation Council for Graduate Medical
Education-accredited training programs in Pulmonary and
Critical Care Medicine in the United States was performed
through the website /www.acgme.org/acWebsite/home/
home.aspS. Each program was contacted to obtain email
addresses of their pulmonary and critical care faculty for use
in administering an anonymous, voluntary electronic survey.
Individual email addresses were requested for direct
distribution of the survey. In cases where individual email
addresses were not available, a central administrative
contact was identified for internal distribution of the survey
at that institution.
This protocol was approved by the Committee on Human
Research at the University of California San Francisco and
the Institutional Review Board at Vanderbilt University.Survey administration
The survey was electronically administered from July 1 to
August 31, 2006 using a professional online survey website /
www.surveymonkey.comS. An introductory email describing
the survey and providing a link for interested respondents
was sent to all faculty or faculty administrative contacts.
This was followed by two reminder emails that were sent
only to those who had yet to respond. Respondents were
allowed to complete a partial survey. Only one response per
respondent was allowed. All responses were anonymous;they could not be linked to any respondent information not
provided in the survey.Data analysis
Individual survey responses were compiled with additional
variables (e.g., combination treatment regimens) created
based on further analysis of the primary survey data. For
determination of region of practice, the United States
Census Bureau regions were adopted. Summary statistics
were calculated and displayed as percentages. Comparisons
across demographic and geographic variables were per-
formed using chi-squared and Fisher’s exact procedures
where appropriate. A p value of o0.05 was considered
statistically significant. All data analyses were performed
using SAS v9.2 (SAS Institute, Cary, NC).Results
Survey respondents
One hundred and thirty training programs were identified.
Eight hundred and thirty-four individual emails were
obtained from 39 programs in 22 states and the District of
Columbia. Three additional institutions provided adminis-
trative email contacts and internally distributed the survey
to their faculty. Assuming an equal number of faculty
at each institution, this pool represents 32% of all
academic pulmonologists. Responses were received from
272 respondents (33% survey response rate), or an estimated
10.5% (33% of 32%) of all academic pulmonologists in the
United States. Information on individual program response
rates was not available as survey responses were anon-
ymous. Respondents were asked to provide some general
demographic information, which is summarized in Table 1.
There was at least one response from all 22 states and the
District of Columbia. Twenty-two (8%) of responses were
incomplete.Diagnosis and monitoring
The overwhelming majority of respondents reported that
HRCT should be obtained in all patients suspected of having
IPF (90%), and that a surgical lung biopsy should be obtained
if the HRCT is atypical (76%). Seventy-one percent reported
that a definitive HRCT could establish the diagnosis of IPF in
the proper clinical setting. A minority of respondents
reported that a surgical biopsy should be obtained in all
patients with IPF (12%). Most respondents did not feel
bronchoscopy was important to the diagnosis of IPF (82%).
Most respondents (85%) reported that analysis of serial
changes in both the forced vital capacity (FVC) and diffusing
capacity for carbon monoxide (DLCO) were used to judge
treatment response. Other commonly reported outcome
measures included breathlessness and dyspnea (74%), 6min
walk test distance (59%), exercise oxygen saturation (55%)
and HRCT appearance (50%).
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Figure 1 (A) Frequency of acute exacerbations: 88% of
respondents felt acute exacerbations occur ‘‘sometimes’’
or ‘‘frequently’’. (B) Outcome of acute exacerbations: 92% of
respondents felt that acute exacerbations were ‘‘sometimes’’
or ‘‘frequently’’ fatal.
Table 1 Respondent characteristics.
Characteristic Number of respondents
(%)
Years in practice
o5 years 55 (22)
5–15 years 92 (36)
415 years 105 (42)
Number of idiopathic pulmonary fibrosis patients seen
annually
None 9 (3)
1–5 93 (37)
5–10 80 (32)
11–20 38 (15)
420 32 (13)
Primary academic position
Clinician educator 105 (42)
Researcher (clinical or basic
science)
128 (51)
Administrative 19 (7)
Geographic region of practice
Midwest 46 (19)
Northeast 54 (21)
South 78 (31)
West 74 (29)
Diagnosis and management of pulmonary fibrosis 2013Screening for comorbidities
Thirty-five percent of respondents routinely screen for sleep
apnea, generally by history and physical examination.
Slightly more respondents (55%) routinely screen for gastro-
esophageal reflux disease, again generally by history.
A minority report screening with pH probe (15%) and barium
swallow (7%). The vast majority of respondents screen for
exertional hypoxemia (87%), generally (59%) with formal
6min walk testing, and for autoimmune disease (92%),
generally with history (87%), antinuclear antibody (95%),
rheumatoid factor (90%) and scl-70 antibody (72%).Acute exacerbation of IPF
Nearly all respondents (97%) reported observing acute
exacerbation of IPF, defined as acute worsening of respira-
tory status with no clear etiology (Fig. 1(A)). Nearly all
respondents (87%) required a combination of subjective
worsening of breathlessness and at least one objective
measure to identify an episode as an acute exacerbation of
IPF. Objective measures commonly required in diagnosing an
acute exacerbation included: worsening oxygenation/gas
exchange (92%), absence of infection (86%), absence of
cardiac events (83%), and absence of pulmonary embolism
(82%). A new opacity identified on the chest CT scan was
required by 49% of respondents.
Fifty-one percent of respondents reported treating acute
exacerbations with corticosteroids alone; another 30%
reported treating with combination corticosteroids andcytotoxic therapy (azathioprine or cyclophosphamide). Eight
percent of respondents reported using anticoagulation for
the treatment of acute exacerbations, usually as a single
agent. Most respondents reported that such events are
highly morbid (Fig. 1(B)).
Pharmacologic therapy
The majority of respondents reported (52%) ‘‘frequently’’ or
‘‘always’’ treating patients with IPF at the time of diagnosis.
Another 35% reported treating patients with IPF ‘‘some-
times’’. Twelve percent reported that they ‘‘rarely’’ or
‘‘never’’ treat IPF with medications. Most first-line treat-
ment regimens (74%) contained prednisone with or without
the addition of immunosuppressive agents and N-acetylcys-
teine (Fig. 2). Twenty-three percent reported using combi-
nation corticosteroid and cytotoxic therapy (azathioprine or
cyclophosphamide). Salvage therapy (i.e., therapy for
patients unresponsive to initial treatment) was much less
likely to include prednisone (18%) and more likely to include
interferon gamma 1b (17%) or no therapy (20%) (Fig. 2).
Respondents seeing fewer than five patients with IPF a year
were more likely to use prednisone alone as a first choice
regimen (p ¼ 0.01) and appeared less likely to report no
therapy as an initial approach (p ¼ 0.08) (Table 2).
Non-pharmacological therapy
Lung transplantation was reported as a treatment option for
IPF by 54% of respondents. There was significant variation in
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use in the midwest (p ¼ 0.01), in respondents in practice for
less than 5 years (p ¼ 0.01) and in respondents seeing over
20 patients with IPF annually (p ¼ 0.0007) (Table 3).
Two-thirds (68%) of respondents reported that they
routinely refer patients with IPF for pulmonary rehabilita-
tion. Of those that do not refer for pulmonary rehabilitation,
the majority (76%) respond that they do not do so because
pulmonary rehabilitation has unproven benefit in IPF. One-
third (32%) of respondents reported presumptively treating
patients with IPF for gastroesophageal reflux disease.Table 2 Initial treatment regimen by various subgroups.
West
(n ¼ 74)
By geographic region
Prednisone only (%) 23
Prednisone plus cytotoxic agent (%) 27
Prednisone, azathioprine, N-acetylcysteine (%) 15
Any prednisone regimen (%)a 65
No therapy (%) 4
By years in practice
Prednisone only (%)
Prednisone plus cytotoxic agent (%)
Prednisone, azathioprine, N-acetylcysteine (%)
Any prednisone regimen (%)a
No therapy (%)
0–5
(n ¼ 102
By number of idiopathic pulmonary fibrosis patients seen annua
Prednisone only (%) 25
Prednisone plus cytotoxic agent (%) 28
Prednisone, azathioprine, N-acetylcysteine (%) 5
Any prednisone regimen (%)a 58
No therapy (%) 7
aAny prednisone regimen combines three choices (prednisone o
prednisone, azathioprine, N-acetylcysteine).
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Figure 2 Pharmacologic therapy in IPF: initial (black bars) and
salvage (gray bars) treatment regiments reported by survey
respondents (n ¼ 260).Discussion
This study represents the first large-scale assessment of
clinical practice patterns of academic physicians caring for
patients with IPF. Importantly, this is the first survey
performed since the publication of the ATS/ERS/ACCP
statement on IPF.2 The findings of this study show the
following: (1) There is general consensus regarding the
approach to diagnosing and monitoring in IPF, and this
approach is largely consistent with the consensus recom-
mendations. The exception is the use of bronchoscopy,
which is recommended but is rarely performed. (2) There is
no consensus about the medical management of patients
with IPF, with a minority of respondents following consensus
treatment recommendations. (3) There is uniform recogni-
tion that acute exacerbations of IPF occur, and that they are
common and highly morbid events. (4) Lung transplantation
is considered as a treatment option by half of academic
pulmonologists.Previous surveys of practice patterns in IPF
In the last 20 years, three surveys of practice patterns in IPF
have been published in the English language literature. In
1989, Smith and colleagues surveyed 109 graduates of the
University of California San Diego pulmonary fellowshipMidwest
(n ¼ 46)
South
(n ¼ 78)
Northeast
(n ¼ 54)
p value
15 14 19 0.51
17 23 22 0.68
13 19 7 0.29
46 56 48 0.13
13 17 4 0.02
o5
(n ¼ 55)
5–15
(n ¼ 92)
415
(n ¼ 105)
p value
15 15 22 0.36
20 25 23 0.78
16 12 15 0.71
51 52 60 0.42
16 8 8 0.15
)
5–10
(n ¼ 80)
11–20
(n ¼ 38)
420
(n ¼ 32)
p value
lly
19 13 0 0.01
18 29 13 0.12
24 13 22 0.002
60 55 34 0.08
6 18 16 0.08
nly; prednisone and either azathioprine or cyclophosphamide;
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Table 3 Use of lung transplantation by various subgroups.
West
(n ¼ 74)
Midwest
(n ¼ 46)
South
(n ¼ 78)
Northeast
(n ¼ 54)
p value
By geographic region
Transplantation (%) 41 70 60 50 0.01
o5 years
(n ¼ 55)
5–15 years
(n ¼ 92)
415 years
(n ¼ 105)
p value
By years in practice
Transplantation (%) 65 60 43 0.09
0–5
(n ¼ 102)
5–10
(n ¼ 80)
11–20
(n ¼ 38)
420
(n ¼ 32)
p value
By number of idiopathic pulmonary fibrosis patients seen annually
Transplantation (%) 41 59 55 81 0.0007
Diagnosis and management of pulmonary fibrosis 2015training program and received 25 analyzable responses (23%
response rate).9 A minority reported routine use of open
biopsy (30%) while a majority reported the use of transbron-
chial biopsy (65%) for the diagnosis of IPF. Initial treatment
was generally with prednisone alone (72%) or prednisone
plus cytotoxic agent (8%). Salvage therapy was most
commonly prednisone plus cytotoxic agent (52%). Disease
monitoring was by pulmonary function tests (80%), exercise
studies (64%) chest X-ray (40%), gallium scan (36%) and
symptoms (32%). Lung transplant was little used (4%), likely
because at that time it was not widely available.
In 1993, Johnson and colleagues published a retrospective
chart review of 200 IPF patients seen in the United
Kingdom.10 They found very few cases were diagnosed
by surgical biopsy (8%), with a larger minority diagnosed
by transbronchial biopsy (33%). Treatment was most
commonly with prednisone alone (55%) and uncommonly
with prednisone plus a cytotoxic agent (11%). Thirty-
four percent received no therapy. A follow up study by
Johnson and colleagues in 1997 utilized a prospective
registry of 558 patients entered by 150 providers over 2
years.11 Their findings confirmed that surgical biopsy was
rare (12%), that prednisone alone remained the most
common therapy (34%), and that 48% of patients received
no therapy.
Our survey expands upon these previous efforts in several
important ways. First, it involves a larger sample of
pulmonologists than any previous study. Secondly, it
provides insight into the current standard of care being
taught to practicing pulmonologists and physicians in
training. Thirdly, it is broader in scope than previous
surveys, investigating diagnosis, pharmacologic and non-
pharmacologic management, natural history, disease mon-
itoring and screening for comorbidities. Fourthly, it is
the only study to incorporate the use of HRCT
scanning. Lastly, it is the only study conducted after
the ATS/ERS/ACCP statement revised the definition of
IPF and recommended an approach to diagnosis and
management, and can therefore comment on the degree
to which expert opinion is being adopted by the larger
academic community.Management patterns in patients with IPF
These results suggest that, unlike diagnosis, the manage-
ment of IPF remains far from standardized; there is no
consensus approach among academic pulmonologists. There
are likely several factors involved. First, recent data on the
impact of corticosteroid and cytotoxic drugs have been
published that suggest a lack of efficacy and confirm the
common occurrence of side effects.12–14 Second, published
studies of agents such as interferon gamma 1b, pirfenidone,
and N-acetylcysteine have been interpreted as showing
promise.15–21 Third, the increasingly accepted pathophysio-
logic paradigm of abnormal wound healing in which
inflammation plays a limited role argues against the
traditional approach to therapy (corticosteroids and cyto-
toxic agents) proposed by the consensus statement.22 In the
absence of compelling data or rationale, pulmonologists are
left to make treatment decisions based on intuition and
anecdote, and this understandably leads to a variety of
approaches.Study limitations and future directions
There are important limitations to our survey. With any
survey, a critical issue is how well respondents represent the
target population. Overall, this survey received responses
from approximately 10% of academic pulmonologists in the
United States. Sampling bias (i.e., bias introduced due to
differences in the intended target population and the cohort
surveyed) is always present, and effort must be made to
reduce its impact. Randomly choosing potential respondents
from the target population is ideal, but not always practical.
In this survey, sampling was not random; emails were sent to
potential respondents based on whether or not their training
program provided contact information. However, a large
percentage of the general population of interest was
surveyed (32%) reducing the impact of sampling bias.
A second important issue is the survey response rate.
Ideally, 100% of those sampled would respond, but again,
this is often impractical, particularly with large, geographi-
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response rate, the more potential for responder bias (i.e.,
those who responded are somehow different from those who
did not). Our response rate of 33% is typical of physician
surveys published in the medical literature.23 Finally, there
is always the potential for survey questions to be mis-
interpreted.
It is hoped that the observations in this survey serve as a
benchmark for understanding how academic physicians
approach the diagnosis and management of IPF. Further,
these results may provide guidance to thought leaders
involved in physician education and practice guideline
development regarding continued educational needs.
Conflict of interest statement: None of the authors has a
conflict of interest to declare in relation to this work.
Acknowledgment
The authors wish to acknowledge the efforts of the 272
participating pulmonologists, and thank them for taking
time from their busy careers to contribute to medical
research.
References
1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster
G. Incidence and prevalence of idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 2006;174(7):810–6.
2. American Thoracic Society. Idiopathic pulmonary fibrosis:
diagnosis and treatment. International consensus statement.
American Thoracic Society (ATS), and the European Respiratory
Society (ERS). Am J Respir Crit Care Med 2000;161:646–64.
3. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance
of histopathologic subsets in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 1998;157:199–203.
4. Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of
histological classification of idiopathic interstitial pneumonia.
Eur Respir J 2002;19(2):275–83.
5. Nicholson AG, Colby TV, Dubois RM, Hansell DM, Wells AU. The
prognostic significance of the histologic pattern of interstitial
pneumonia in patients presenting with the clinical entity of
cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med
2000;162:2213–7.
6. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological
versus histological diagnosis in UIP and NSIP: survival implica-
tions. Thorax 2003;58(2):143–8.
7. Hunninghake G, Zimmerman MB, Schwartz DA, et al. Utility of
lung biopsy for the diagnosis of idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 2001;164:193–6.
8. Raghu G, Mageto YN, Lockhart D, et al. The accuracy of the
clinical diagnosis of new-onset idiopathic pulmonary fibrosis andother interstitial lung disease: a prospective study. Chest 1999;
116(5):1168–74.
9. Smith CM, Moser KM. Management for interstitial lung disease.
State of the art. Chest 1989;95(3):676–8.
10. Johnston ID, Gomm SA, Kalra S, et al. The management of
cryptogenic fibrosing alveolitis in three regions of the United
Kingdom [see comments]. Eur Respir J 1993;6(6):891–3.
11. Johnston ID, Prescott RJ, Chalmers JC, Rudd RM. British
Thoracic Society study of cryptogenic fibrosing alveolitis:
current presentation and initial management. Fibrosing Alveo-
litis Subcommittee of the Research Committee of the British
Thoracic Society. Thorax 1997;52(1):38–44.
12. Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroid
and cyclophosphamide therapy does not alter survival in
idiopathic pulmonary fibrosis. Chest 2004;125(6):2169–74.
13. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary
fibrosis: impact of oxygen and colchicine, prednisone, or no
therapy on survival. Am J Respir Crit Care Med 2000;161(4 Pt
1):1172–8.
14. Flaherty KR, Toews GB, Lynch JPIII, et al. Steroids in idiopathic
pulmonary fibrosis: a prospective assessment of adverse
reactions, response to therapy, and survival. Am J Med 2001;
110:278–82.
15. Bajwa EK, Ayas NT, Schulzer M, et al. Interferon-gamma1b
therapy in idiopathic pulmonary fibrosis: a metaanalysis. Chest
2005;128(1):203–6.
16. King Jr. TE, Safrin S, Starko KM, et al. Analyses of efficacy end
points in a controlled trial of interferon-{gamma}1b for
idiopathic pulmonary fibrosis. Chest 2005;127(1):171–7.
17. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled
trial of interferon gamma-1b in patients with idiopathic
pulmonary fibrosis. N Engl J Med 2004;350(2):125–33.
18. Strieter RM, Starko KM, Enelow RI, Noth I, Valentine VG. Effects
of interferon-gamma 1b on biomarker expression in patients
with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med
2004;170(2):133–40.
19. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-
controlled trial of pirfenidone in patients with idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med 2005;171(9):
1040–7.
20. Azuma A, Tsuboi E, Abe S, et al. A placebo control and double
blind phase ii clinical study of pirfenidone in patients with
idiopathic pulmonary fibrosis in Japan. Am J Respir Crit Care
Med 2002;165:A729.
21. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in
idiopathic pulmonary fibrosis. N Engl J Med 2005;353(21):
2229–42.
22. Selman M, King Jr. TE, Pardo A. Idiopathic pulmonary fibrosis:
prevailing and evolving hypotheses about its pathogenesis
and implications for therapy. Ann Intern Med 2001;134:
136–51.
23. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail
surveys published in medical journals. J Clin Epidemiol 1997;
50(10):1129–36.
